- Home
- GLT vs MIST Comparison
GLT vs MIST Comparison
Compare GLT & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLT
- MIST
- Stock Information
- Founded
- GLT 1864
- MIST 2003
- Country
- GLT United States
- MIST Canada
- Employees
- GLT N/A
- MIST N/A
- Industry
- GLT Paper
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- GLT Basic Materials
- MIST Health Care
- Exchange
- GLT Nasdaq
- MIST Nasdaq
- Market Cap
- GLT 81.5M
- MIST 81.5M
- IPO Year
- GLT N/A
- MIST N/A
- Fundamental
- Price
- GLT $1.73
- MIST $1.47
- Analyst Decision
- GLT
- MIST Strong Buy
- Analyst Count
- GLT 0
- MIST 3
- Target Price
- GLT N/A
- MIST $13.00
- AVG Volume (30 Days)
- GLT 259.4K
- MIST 89.0K
- Earning Date
- GLT 10-31-2024
- MIST 11-11-2024
- Dividend Yield
- GLT N/A
- MIST N/A
- EPS Growth
- GLT N/A
- MIST N/A
- EPS
- GLT N/A
- MIST N/A
- Revenue
- GLT $1,307,002,000.00
- MIST N/A
- Revenue This Year
- GLT N/A
- MIST N/A
- Revenue Next Year
- GLT N/A
- MIST N/A
- P/E Ratio
- GLT N/A
- MIST N/A
- Revenue Growth
- GLT N/A
- MIST N/A
- 52 Week Low
- GLT $1.22
- MIST $1.12
- 52 Week High
- GLT $2.71
- MIST $3.52
- Technical
- Relative Strength Index (RSI)
- GLT 50.77
- MIST 46.08
- Support Level
- GLT $1.67
- MIST $1.49
- Resistance Level
- GLT $1.81
- MIST $1.65
- Average True Range (ATR)
- GLT 0.09
- MIST 0.07
- MACD
- GLT -0.01
- MIST -0.01
- Stochastic Oscillator
- GLT 33.33
- MIST 18.18
About GLT Glatfelter Corporation
Glatfelter Corporation manufactures and sells a variety of paper and fiber products. The company's reportable segments are; Composite Fibers, Spunlace. and Airlaid Materials. The Airlaid Materials segment which is also its key revenue generating segment, is a supplier of cellulose-based airlaid nonwoven materials used to manufacture consumer products for end-user markets. The Airlaid Materials segment produces materials used in feminine hygiene, specialty wipes, tabletop, home care, and other consumables. Geographically, the company derives majority of its revenue from Americas and rest from Europe, Middle East, Africa and Asia Pacific markets.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).